Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
1. A method of treating a disease or disorder selected from Crohn's Disease or ulcerative colitis, the method comprising administering to a patient having a Crohn's Disease or ulcerative colitis a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 further comprising administering to the patient a therapeutically effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti-inflammatory drug, or steroid.
3. The method of claim 1 wherein the compound is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.
4. The method of claim 3 wherein the compound is administered orally.
5. The method of claim 4 wherein the compound is administered orally in a tablet or capsule form.
6. The method of claim 1 wherein the therapeutically effective amount is from about 1 mg to about 1000 mg per day.
7. The method of claim 6 wherein the therapeutically effective amount is from about 5 mg to about 500 mg per day.
8. The method of claim 7 wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day.
9. The method of claim 1 , wherein the disease or disorder is Crohn's Disease.
10. The method of claim 1 , wherein the disease or disorder is ulcerative colitis.
11. The method of claim 4 , wherein the compound is administered twice daily in equally divided doses.
12. The method of claim 4 , wherein the stereomerically pure compound comprises greater than about 90% by weight of (+) isomer based on the total weight percent of the compound.
13. The method of claim 4 , wherein the stereomerically pure compound comprises greater than about 95% by weight of (+) isomer based on the total weight percent of the compound.
14. The method of claim 4 , wherein the stereomerically pure compound comprises greater than about 97% by weight of (+) isomer based on the total weight percent of the compound.
15. The method of claim 5 , wherein the capsule contains about 10 mg of the compound.
16. The method of claim 5 , wherein the capsule contains about 20 mg of the compound.
17. The method of claim 5 , wherein the capsule contains about 25 mg of the compound.
18. The method of claim 5 , wherein the capsule contains about 50 mg of the compound.
19. The method of claim 5 , wherein the tablet contains about 10 mg of the compound.
20. The method of claim 5 , wherein the tablet contains about 20 mg of the compound.
21. The method of claim 5 , wherein the tablet contains about 25 mg of the compound.
22. The method of claim 5 , wherein the tablet contains about 50 mg of the compound.
23. A method of treating Crohn's Disease, which comprises orally administering to a patient having Crohn's Disease about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer, wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.
24. A method of treating ulcerative colitis, which comprises orally administering to a patient having ulcerative colitis about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer, wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.